Lei Deng
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Lei Deng has a total of 69 co-authors. Here are the top co-authors by number of shared publications:
- De-Jian Liu
Hunan Provincial Key Laboratory of Medical Virology, College of Biology, Hunan University, Changsha 410082, China
6 shared publications Shi-Long Zhao
Hunan Provincial Key Laboratory of Medical Virology, Institute of Pathogen Biology and Immunology, College of Biology, Hunan University, Changsha, China
5 shared publicationsCui-Cui Liu
Hunan Provincial Key Laboratory of Medical Virology, Institute of Pathogen Biology and Immunology, College of Biology, Hunan University, Changsha, China
4 shared publicationsXiu-Qin Zhong
Changsha Medical University
4 shared publicationsXuan Wu
Hunan Provincial Key Laboratory of Medical Virology, Institute of Pathogen Biology and Immunology, College of Biology, Hunan University, Changsha, China
4 shared publicationsDe-Jian Liu
Department of Epidemiology, School of Public Health, Zhengzhou University, Zhengzhou, China
3 shared publications
Latest Publications
- Open Access
- 26 August 2026
- Published by Elsevier in SSRN Electronic Journal
Cross-Group Influenza A Protection by Single-Dose Scaffold-Free H1 Stem mRNA Vaccination
The conserved hemagglutinin (HA) stem region is an ideal target for universal influenza vaccine development. We aimed to develop a novel scaffold-free H1 stem vaccine candidate. Via structure-based stepwise engineering of the protomer interface under a holistic balance design philosophy, the trimeric H1 stem-only protein designated #219 was generated and stabilized via artificial disulfide restraints and optimized hydrophobic core packing, which fundamentally eliminates off-target immune response risks. The 2.97 Å-resolution cryo-EM structural model validates the native architecture of #219, showing authentic residue interactions with paratopes of five classic broadly neutralizing antibodies targeting conserved intraprotomer or interprotomer epitopes respectively. Single intramuscular 5 μg dose of mRNA expressing membrane-anchored #219 bearing I77Y induced broad cross-protection in mice, fully protecting against lethal H1N1 and H5N1 challenges, while booster vaccination even conferred complete H7N9 protection. It is plausible that the faithfully recapitulated native conformation can augment antibody responses targeting rare cross-group protective epitopes. The resulting serum antibodies exhibited potent cross-reactivity against H1, H2, H5, with detectable binding to H7 and B/HAs. Combined immunization with the mRNA vaccine and commercial seasonal quadrivalent vaccine generated additive and complementary protective immunity without evident antigenic interference, and expanded stem-specific memory B cells to ~0.28% of total memory B cells. Collectively, our proof-of-concept study reports a promising universal influenza vaccine candidate, and the protein design philosophy can be referable for stability engineering aimed at exclusive retention of defined epitopes from truncated homo-oligomeric proteins.
- 26 August 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessCross-Group Influenza A Protection by Single-Dose Scaffold-Free H1 Stem mRNA Vaccination
The conserved hemagglutinin (HA) stem region is an ideal target for universal influenza vaccine development. We aimed to develop a novel scaffold-free H1 stem vaccine candidate. Via structure-based stepwise engineering of the protomer interface under a holistic balance design philosophy, the trimeric H1 stem-only protein designated #219 was generated and stabilized via artificial disulfide restraints and optimized hydrophobic core packing, which fundamentally eliminates off-target immune response risks. The 2.97 Å-resolution cryo-EM structural model validates the native architecture of #219, showing authentic residue interactions with paratopes of five classic broadly neutralizing antibodies targeting conserved intraprotomer or interprotomer epitopes respectively. Single intramuscular 5 μg dose of mRNA expressing membrane-anchored #219 bearing I77Y induced broad cross-protection in mice, fully protecting against lethal H1N1 and H5N1 challenges, while booster vaccination even conferred complete H7N9 protection. It is plausible that the faithfully recapitulated native conformation can augment antibody responses targeting rare cross-group protective epitopes. The resulting serum antibodies exhibited potent cross-reactivity against H1, H2, H5, with detectable binding to H7 and B/HAs. Combined immunization with the mRNA vaccine and commercial seasonal quadrivalent vaccine generated additive and complementary protective immunity without evident antigenic interference, and expanded stem-specific memory B cells to ~0.28% of total memory B cells. Collectively, our proof-of-concept study reports a promising universal influenza vaccine candidate, and the protein design philosophy can be referable for stability engineering aimed at exclusive retention of defined epitopes from truncated homo-oligomeric proteins.
- 17 June 2026
- Published by Elsevier in International Journal of Pharmaceutics
- Vol. 701, 127088
Perspectives on chikungunya vaccinology: from traditional platforms to epitope-driven rational design
- 17 June 2026
- Published by Elsevier in International Journal of Pharmaceutics
- Vol. 701, 127088
Perspectives on chikungunya vaccinology: from traditional platforms to epitope-driven rational design
- Open Access
- 1 April 2026
- Published by KEAI Publishing in Virologica Sinica
- Vol. 41 (2) , 261-275
Structural vaccinology expedites rational design of next-generation vaccines for influenza and respiratory syncytial virus
Vaccination stands as the single most effective and cost-efficient public health intervention in human history, serving as a cornerstone of modern medicine that profoundly transforms global health outcomes. Beyond preventing disease, it acts as a catalyst for equitable socioeconomic development. In recent decades, recurrent seasonal viral outbreaks and sporadic yet catastrophic pandemics, have continued to pose challenges to global public health systems. Traditional vaccine technologies, however, not only often fall short in protection efficacy, but also fail to keep pace with the evolving demands of next-generation vaccine development. These scientific gaps have directed cutting-edge research to prioritize critical objectives in terms of enhancing antigen effectiveness, achieving stable pan-protection against diverse variant strains, and strengthening production robustness. The advent of genomics spurred the emergence of reverse vaccinology 1.0, leading to breakthroughs like the MenB vaccine. Today, the advanced reverse vaccinology 2.0 paradigm thoroughly redefines vaccine design process by organically integrating human immunology with state-of-the-art computational protein structure analysis tools. This review explores the transformative shifts in influenza and respiratory syncytial virus vaccine development, along with specific case studies, to deepen understanding of the evolving principles and methodologies in novel vaccine designs and offer strategic insights for addressing emerging infectious pathogens.
- 1 April 2026
- Published by KEAI Publishing in Virologica Sinica
- Vol. 41 (2) , 261-275
Open AccessStructural vaccinology expedites rational design of next-generation vaccines for influenza and respiratory syncytial virus
Vaccination stands as the single most effective and cost-efficient public health intervention in human history, serving as a cornerstone of modern medicine that profoundly transforms global health outcomes. Beyond preventing disease, it acts as a catalyst for equitable socioeconomic development. In recent decades, recurrent seasonal viral outbreaks and sporadic yet catastrophic pandemics, have continued to pose challenges to global public health systems. Traditional vaccine technologies, however, not only often fall short in protection efficacy, but also fail to keep pace with the evolving demands of next-generation vaccine development. These scientific gaps have directed cutting-edge research to prioritize critical objectives in terms of enhancing antigen effectiveness, achieving stable pan-protection against diverse variant strains, and strengthening production robustness. The advent of genomics spurred the emergence of reverse vaccinology 1.0, leading to breakthroughs like the MenB vaccine. Today, the advanced reverse vaccinology 2.0 paradigm thoroughly redefines vaccine design process by organically integrating human immunology with state-of-the-art computational protein structure analysis tools. This review explores the transformative shifts in influenza and respiratory syncytial virus vaccine development, along with specific case studies, to deepen understanding of the evolving principles and methodologies in novel vaccine designs and offer strategic insights for addressing emerging infectious pathogens.
- 19 March 2025
- Published by Elsevier in International Journal of Biological Macromolecules
- Vol. 307 (Pt 4) , 142240
Soluble influenza H3 trimer proteins enhance the breadth and potency of antibody response
- 19 March 2025
- Published by Elsevier in International Journal of Biological Macromolecules
- Vol. 307 (Pt 4) , 142240
Soluble influenza H3 trimer proteins enhance the breadth and potency of antibody response
- Open Access
- 17 October 2024
- Published by Springer Nature in Research Square
Structure-based design of a broadly protective influenza hemagglutinin stem immunogen
The conserved hemagglutinin (HA) stem region is widely regarded as a highly promising target for the development of a universal influenza vaccine. Through structure-based design and iterative mutagenesis screening, we successfully engineered a soluble trimeric H1 stem-only protein, designated #219, which does not contain heterologous trimerization motifs and thus prevents off-target immune responses. As confirmed by a 2.97 Å-resolution cryo-EM structure, the overall conformation of #219 remains intact. Vaccination of mice with #219 protected against lethal heterologous viral challenges. Specific serum antibodies strongly cross-reacted with HAs of diverse influenza A subtypes, cross-neutralized various H1N1 viruses, and exhibited multiple antibody-effector functions mediating infection-permissive protection. We have developed a promising H1 stem immunogen for broad cross-protection against influenza infection and also proposed an efficacious design strategy for soluble homo-oligomeric proteins.
- 17 October 2024
- Published by Springer Nature in Research Square
Open AccessStructure-based design of a broadly protective influenza hemagglutinin stem immunogen
The conserved hemagglutinin (HA) stem region is widely regarded as a highly promising target for the development of a universal influenza vaccine. Through structure-based design and iterative mutagenesis screening, we successfully engineered a soluble trimeric H1 stem-only protein, designated #219, which does not contain heterologous trimerization motifs and thus prevents off-target immune responses. As confirmed by a 2.97 Å-resolution cryo-EM structure, the overall conformation of #219 remains intact. Vaccination of mice with #219 protected against lethal heterologous viral challenges. Specific serum antibodies strongly cross-reacted with HAs of diverse influenza A subtypes, cross-neutralized various H1N1 viruses, and exhibited multiple antibody-effector functions mediating infection-permissive protection. We have developed a promising H1 stem immunogen for broad cross-protection against influenza infection and also proposed an efficacious design strategy for soluble homo-oligomeric proteins.
- Open Access
- 18 August 2024
- Published by Taylor & Francis in Emerging Microbes & Infections
- Vol. 13 (1) , 2389095
Disulfide-stabilized trimeric hemagglutinin ectodomains provide enhanced heterologous influenza protection
Influenza virus infection poses a continual menace to public health. Here, we developed soluble trimeric HA ectodomain vaccines by establishing interprotomer disulfide bonds in the stem region, which effectively preserve the native antigenicity of stem epitopes. The stable trimeric H1 ectodomain proteins exhibited higher thermal stabilities in comparison with unmodified HAs and showed strong binding activities towards a panel of anti-stem cross-reactive antibodies that recognize either interprotomer or intraprotomer epitopes. Negative stain transmission electron microscopy (TEM) analysis revealed the stable trimer architecture of the interprotomer disulfide-stapled WA11#5, NC99#2, and FLD#1 proteins as well as the irregular aggregation of unmodified HA molecules. Immunizations of mice with those trimeric HA ectodomain vaccines formulated with incomplete Freund's adjuvant elicited significantly more potent cross-neutralizing antibody responses and offered broader immuno-protection against lethal infections with heterologous influenza strains compared to unmodified HA proteins. Additionally, the findings of our study indicate that elevated levels of HA stem-specific antibody responses correlate with strengthened cross-protections. Our design strategy has proven effective in trimerizing HA ectodomains derived from both influenza A and B viruses, thereby providing a valuable reference for designing future influenza HA immunogens.
- 18 August 2024
- Published by Taylor & Francis in Emerging Microbes & Infections
- Vol. 13 (1) , 2389095
Open AccessDisulfide-stabilized trimeric hemagglutinin ectodomains provide enhanced heterologous influenza protection
Influenza virus infection poses a continual menace to public health. Here, we developed soluble trimeric HA ectodomain vaccines by establishing interprotomer disulfide bonds in the stem region, which effectively preserve the native antigenicity of stem epitopes. The stable trimeric H1 ectodomain proteins exhibited higher thermal stabilities in comparison with unmodified HAs and showed strong binding activities towards a panel of anti-stem cross-reactive antibodies that recognize either interprotomer or intraprotomer epitopes. Negative stain transmission electron microscopy (TEM) analysis revealed the stable trimer architecture of the interprotomer disulfide-stapled WA11#5, NC99#2, and FLD#1 proteins as well as the irregular aggregation of unmodified HA molecules. Immunizations of mice with those trimeric HA ectodomain vaccines formulated with incomplete Freund's adjuvant elicited significantly more potent cross-neutralizing antibody responses and offered broader immuno-protection against lethal infections with heterologous influenza strains compared to unmodified HA proteins. Additionally, the findings of our study indicate that elevated levels of HA stem-specific antibody responses correlate with strengthened cross-protections. Our design strategy has proven effective in trimerizing HA ectodomains derived from both influenza A and B viruses, thereby providing a valuable reference for designing future influenza HA immunogens.
- Open Access
Sequential Immunizations with Influenza Neuraminidase Protein Followed by Peptide Nanoclusters Induce Heterologous Protection
Enhancing cross-protections against diverse influenza viruses is desired for influenza vaccinations. Neuraminidase (NA)-specific antibody responses have been found to independently correlate with a broader influenza protection spectrum. Here, we report a sequential immunization regimen that includes priming with NA protein followed by boosting with peptide nanoclusters, with which targeted enhancement of antibody responses in BALB/c mice to certain cross-protective B-cell epitopes of NA was achieved. The nanoclusters were fabricated via desolvation with absolute ethanol and were only composed of composite peptides. Unlike KLH conjugates, peptide nanoclusters would not induce influenza-unrelated immunity. We found that the incorporation of a hemagglutinin peptide of H2-d class II restriction into the composite peptides could be beneficial in enhancing the NA peptide-specific antibody response. Of note, boosters with N2 peptide nanoclusters induced stronger serum cross-reactivities to heterologous N2 and even heterosubtypic N7 and N9 than triple immunizations with the prototype recombinant tetrameric (rt) N2. The mouse challenge experiments with HK68 H3N2 also demonstrated the strong effectiveness of the peptide nanocluster boosters in conferring heterologous protection.
Open AccessSequential Immunizations with Influenza Neuraminidase Protein Followed by Peptide Nanoclusters Induce Heterologous Protection
Enhancing cross-protections against diverse influenza viruses is desired for influenza vaccinations. Neuraminidase (NA)-specific antibody responses have been found to independently correlate with a broader influenza protection spectrum. Here, we report a sequential immunization regimen that includes priming with NA protein followed by boosting with peptide nanoclusters, with which targeted enhancement of antibody responses in BALB/c mice to certain cross-protective B-cell epitopes of NA was achieved. The nanoclusters were fabricated via desolvation with absolute ethanol and were only composed of composite peptides. Unlike KLH conjugates, peptide nanoclusters would not induce influenza-unrelated immunity. We found that the incorporation of a hemagglutinin peptide of H2-d class II restriction into the composite peptides could be beneficial in enhancing the NA peptide-specific antibody response. Of note, boosters with N2 peptide nanoclusters induced stronger serum cross-reactivities to heterologous N2 and even heterosubtypic N7 and N9 than triple immunizations with the prototype recombinant tetrameric (rt) N2. The mouse challenge experiments with HK68 H3N2 also demonstrated the strong effectiveness of the peptide nanocluster boosters in conferring heterologous protection.
- Open Access
- 6 October 2023
- Published by Springer Nature in Research Square
Secretory Hemagglutinin Ectodomains Trimerized by Interprotomer Disulfide Bonds Provide Strong Cross-protection Against Influenza A and B Viruses
The stable secretory expression of HA ectodomain would in principle enhance the yield of influenza vaccine. However, without the transmembrane domain, the folded conformation of the ectodomain polypeptide would most likely deviate from its native form, which poses a risk of antigenicity impairment. Here we comprehensively describe all putative patterns of interprotomer disulfide bridges in HA using computer simulation, among which some pairs of cysteine insets forcefully drive the formation of homotrimers with strong antigenicity to a panel of anti-stem cross-reactive antibodies. Negative-stain 2-D class averaging showed the vast majority of the NC99#2 H1 molecules as homogeneous trimers, while the unmodified H1 protomers were irregularly aggregated. Immunizations of mice with the stabilized HA improved cross-protection by the robust elicitation of serum cross-neutralization instead of hemagglutination inhibition activities. Our study bears significant practical implications for developing secretory HA-based influenza vaccines.
- 6 October 2023
- Published by Springer Nature in Research Square
Open AccessSecretory Hemagglutinin Ectodomains Trimerized by Interprotomer Disulfide Bonds Provide Strong Cross-protection Against Influenza A and B Viruses
The stable secretory expression of HA ectodomain would in principle enhance the yield of influenza vaccine. However, without the transmembrane domain, the folded conformation of the ectodomain polypeptide would most likely deviate from its native form, which poses a risk of antigenicity impairment. Here we comprehensively describe all putative patterns of interprotomer disulfide bridges in HA using computer simulation, among which some pairs of cysteine insets forcefully drive the formation of homotrimers with strong antigenicity to a panel of anti-stem cross-reactive antibodies. Negative-stain 2-D class averaging showed the vast majority of the NC99#2 H1 molecules as homogeneous trimers, while the unmodified H1 protomers were irregularly aggregated. Immunizations of mice with the stabilized HA improved cross-protection by the robust elicitation of serum cross-neutralization instead of hemagglutination inhibition activities. Our study bears significant practical implications for developing secretory HA-based influenza vaccines.
- Open Access
Immunities Specific to Both of the M Protein Ectodomain and RBD Synergize to Confer Cross-protection against SARS-CoV-2 Infections
The effectiveness of the prototypic SARS-CoV-2 vaccine largely decreased overtime against the emerging virus strains, necessitating the universal vaccine development. The most abundant structural membrane (M) protein is highly conserved in amino acid sequence, which arouses our research interests in developing a universal immunogen based on it. Serological analysis showed that IgG responses specific to its N-terminal peptides can be strongly detected in many serum samples from both convalescent patients and vaccinees receiving inactivated vaccines, indicating the potential existence of human B-cell epitopes in reactive peptides. Microneutralization assays showed that the N-terminal peptide S2M2-30-specific hyperimmune serum was capable of cross-neutralizing the authentic viruses including wild-type HKU-001a, B.1.617.2/Delta, and Omicron subvariant BQ.1.1, and synergized with RBD-specific serum in reinforcing antiviral activities. Strong S2M2-30-specific immunities elicited in hACE2-transgenic mice could effectively inhibit B.1.1.7/Alpha (UK) infections. Our results suggest the potentiality of conserved M peptides as vaccine targets for conferring cross-protections against sarbecoviruses.
Open AccessImmunities Specific to Both of the M Protein Ectodomain and RBD Synergize to Confer Cross-protection against SARS-CoV-2 Infections
The effectiveness of the prototypic SARS-CoV-2 vaccine largely decreased overtime against the emerging virus strains, necessitating the universal vaccine development. The most abundant structural membrane (M) protein is highly conserved in amino acid sequence, which arouses our research interests in developing a universal immunogen based on it. Serological analysis showed that IgG responses specific to its N-terminal peptides can be strongly detected in many serum samples from both convalescent patients and vaccinees receiving inactivated vaccines, indicating the potential existence of human B-cell epitopes in reactive peptides. Microneutralization assays showed that the N-terminal peptide S2M2-30-specific hyperimmune serum was capable of cross-neutralizing the authentic viruses including wild-type HKU-001a, B.1.617.2/Delta, and Omicron subvariant BQ.1.1, and synergized with RBD-specific serum in reinforcing antiviral activities. Strong S2M2-30-specific immunities elicited in hACE2-transgenic mice could effectively inhibit B.1.1.7/Alpha (UK) infections. Our results suggest the potentiality of conserved M peptides as vaccine targets for conferring cross-protections against sarbecoviruses.
- Open Access
- 7 July 2023
- Published by Elsevier in Cell Reports
- Vol. 42 (7) , 112766
Boost immunizations with NA-derived peptide conjugates achieve induction of NA inhibition antibodies and heterologous influenza protections
- 7 July 2023
- Published by Elsevier in Cell Reports
- Vol. 42 (7) , 112766
Open AccessBoost immunizations with NA-derived peptide conjugates achieve induction of NA inhibition antibodies and heterologous influenza protections